title: Tolterodine extended release improves patient-reported outcomes in overactive bladder: results from the IMPACT trial.
abstract: We evaluated the effect of tolterodine extended release (ER) on patient- and clinician-reported outcomes in a primary care setting. Patients had overactive bladder (OAB) symptoms for >or=3 months and were at least moderately bothered by their most bothersome symptom, as indicated on the patient-completed OAB Bother Rating Scale. Patients completed the Overactive Bladder Questionnaire (OAB-q), American Urological Association Symptom Index (AUA-SI), and Patient Perception of Bladder Condition at each visit; investigators completed the Clinical Global Impression-Improvement at week 12. By week 12, there were statistically significant and clinically meaningful decreases on the OAB-q and AUA-SI total and subscale scores (p < 0.0001). Seventy-nine per cent of patients experienced some improvement in their overall bladder condition. Physicians reported that 68% of patients were 'much improved' or 'very much improved'. For symptom-defined conditions, patient-reported outcomes are a valuable means for determining responses to treatment.
authors.affiliation: University of Wisconsin School of Medicine and Public Health, Madison, USA. rroberts@fammed.wisc.edu
authors.forename: R
authors.initials: R
authors.lastname: Roberts
authors.forename: T
authors.initials: T
authors.lastname: Bavendam
authors.forename: D B
authors.initials: DB
authors.lastname: Glasser
authors.forename: M
authors.initials: M
authors.lastname: Carlsson
authors.forename: N
authors.initials: N
authors.lastname: Eyland
authors.forename: V
authors.initials: V
authors.lastname: Elinoff
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001559:Benzhydryl Compounds / Q000008:administration & dosage*; D003408:Cresols / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000008:administration & dosage*; D017060:Patient Satisfaction; D010665:Phenylpropanolamine / Q000008:administration & dosage*; D011788:Quality of Life; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy / Q000209:etiology
chemical_list: D001559:Benzhydryl Compounds; D003408:Cresols; D003692:Delayed-Action Preparations; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate